There is potential for early detection of disease using samples such as blood serum obtained during testing conducted during physical examinations or medical treatment for chronic conditions. High-throughput proteomic mass spectral technologies could potentially be incorporated into automated analyzers in existing laboratories. There are barriers both administrative and scientific before this potential can be realized. We mention this last data source because of its potential to detect disease during the incubation period (prior to symptoms).
Was this article helpful?